ATE205085T1 - Spirooxathiolan-quinuclidin-derivat zur behandlung von xerostomie - Google Patents

Spirooxathiolan-quinuclidin-derivat zur behandlung von xerostomie

Info

Publication number: ATE205085T1
Authority: AT; Austria
Prior art keywords: xerostomia; salivary gland; alkyl; treatment; therapeutic agent
Prior art date: 1994-06-27

Application number

AT95304449T

Other languages

English (en)

Inventor

Harumi Handa

Yasuyoshi Takeshita

Original Assignee

Snow Brand Milk Products Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-06-27

Filing date

1995-06-22

Publication date

2001-09-15

1995-06-22 Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd

2001-09-15 Application granted granted Critical

2001-09-15 Publication of ATE205085T1 publication Critical patent/ATE205085T1/de

Links

206010013781 dry mouth Diseases 0.000 title abstract 4
208000005946 Xerostomia Diseases 0.000 title abstract 3
UANSQQFYKHHDJM-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=CC2=C1 UANSQQFYKHHDJM-KRWDZBQOSA-N 0.000 title 1
239000003814 drug Substances 0.000 abstract 3
210000003079 salivary gland Anatomy 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 2
125000003118 aryl group Chemical group 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
229940124597 therapeutic agent Drugs 0.000 abstract 2
208000030507 AIDS Diseases 0.000 abstract 1
208000031886 HIV Infections Diseases 0.000 abstract 1
208000037357 HIV infectious disease Diseases 0.000 abstract 1
208000019914 Mental Fatigue Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
230000003902 lesion Effects 0.000 abstract 1
230000017074 necrotic cell death Effects 0.000 abstract 1
238000001959 radiotherapy Methods 0.000 abstract 1
210000003296 saliva Anatomy 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000028327 secretion Effects 0.000 abstract 1
230000009885 systemic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Mechanical Treatment Of Semiconductor (AREA)

AT95304449T 1994-06-27 1995-06-22 Spirooxathiolan-quinuclidin-derivat zur behandlung von xerostomie ATE205085T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP6168982A JP2852608B2 (ja)	1994-06-27	1994-06-27	口腔乾燥症治療剤

Publications (1)

Publication Number	Publication Date
ATE205085T1 true ATE205085T1 (de)	2001-09-15

Family

ID=15878165

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95304449T ATE205085T1 (de)	1994-06-27	1995-06-22	Spirooxathiolan-quinuclidin-derivat zur behandlung von xerostomie

Country Status (15)

Country	Link
US (1)	US5580880A (de)
EP (1)	EP0689836B1 (de)
JP (1)	JP2852608B2 (de)
KR (1)	KR100322042B1 (de)
AT (1)	ATE205085T1 (de)
AU (1)	AU707236B2 (de)
CA (1)	CA2152420A1 (de)
CY (1)	CY2290B1 (de)
DE (1)	DE69522511T2 (de)
DK (1)	DK0689836T3 (de)
ES (1)	ES2163474T3 (de)
IL (1)	IL114256A (de)
NO (1)	NO309454B1 (de)
TW (1)	TW401298B (de)
ZA (1)	ZA955317B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9618341D0 (en) *	1996-09-03	1996-10-16	Scotia Holdings Plc	Method of treatment
JP4447685B2 (ja) *	1999-01-14	2010-04-07	第一三共株式会社	皮膚乾燥症治療剤
JP4909809B2 (ja) *	1999-03-24	2012-04-04	生化学工業株式会社	人工唾液
US20110150974A1 (en) *	2004-08-06	2011-06-23	Daiichi Pharmaceutical Co., Ltd.	Agent For Oral Mucosal Administration
EP2258358A3 (de)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenese durch modulation des Muscarinrezeptors
US20070077300A1 (en) *	2005-09-30	2007-04-05	Wynn David W	Oral compositions containing a salivation inducing agent
EP1940389A2 (de)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation von neurogenese durch pde-hemmung
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
JP2009536667A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	５ｈｔ受容体介在性の神経新生
EP2382975A3 (de)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenese mittels Angiotensin-Modulation
AU2007292848A1 (en) *	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US9161909B2 (en) *	2007-08-24	2015-10-20	Axiomedic Ltd.	Adhesive compositions for the treatment of xerostomia
US20090053309A1 (en) *	2007-08-24	2009-02-26	Axiomedic Ltd., Gibraltar	Adhesive compositions for the treatment of xerostomia
US9597278B2 (en)	2008-11-13	2017-03-21	David A. Hamlin	Compositions and methods for alleviating hyposalivation and for providing oral comfort
US9884082B2 (en)	2008-11-13	2018-02-06	David A. Hamlin	Compositions and methods for alleviating hyposalivation and for providing oral comfort
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
US8450487B2 (en) *	2010-06-08	2013-05-28	Apicore, Llc	Process for the preparation of cis-2-methylspiro (1,3-oxathiolane 5-3′) quinuclidine
EP3384786B1 (de)	2015-12-04	2022-03-09	San-Ei Gen F.F.I., INC.	Verwendung von enzymmodifiziertem isoquercitrin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4855290A (en) *	1985-05-10	1989-08-08	State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research	Derivatives of quinuclidine
US5078129A (en) *	1987-05-01	1992-01-07	Research Foundation Of State University Of New York	Device for stimulating salivation
IL87234A (en)	1987-08-13	1992-02-16	Israel Inst Biolog Res	Optical isomers of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine,their preparation and pharmaceutical compositions containing them
US4917674A (en) *	1988-04-04	1990-04-17	Molinoff Henry C	Mouth moisturizing device
US4906455A (en) *	1988-04-15	1990-03-06	Wm. Wrigley Jr. Company	Method for treating xerostomia employing chewing gum containing relatively insoluble, hydrophobic, food-grade organic acid
US4983378A (en) *	1988-11-22	1991-01-08	Parnell Pharmaceuticals, Inc.	Method and composition for treating xerostomia
US4997654A (en) *	1989-08-14	1991-03-05	Warner-Lambert Company	Method for increasing salivation for xerostomia patients
JP3018494B2 (ja) *	1990-11-30	2000-03-13	ソニー株式会社	特殊効果装置
JP2683783B2 (ja) *	1992-07-10	1997-12-03	雪印乳業株式会社	シェーグレン症候群治療剤

1994
- 1994-06-27 JP JP6168982A patent/JP2852608B2/ja not_active Expired - Fee Related
1995
- 1995-06-06 US US08/466,373 patent/US5580880A/en not_active Expired - Lifetime
- 1995-06-10 KR KR1019950015296A patent/KR100322042B1/ko not_active Expired - Fee Related
- 1995-06-21 IL IL11425695A patent/IL114256A/xx not_active IP Right Cessation
- 1995-06-21 TW TW084106358A patent/TW401298B/zh not_active IP Right Cessation
- 1995-06-21 AU AU23245/95A patent/AU707236B2/en not_active Ceased
- 1995-06-22 DK DK95304449T patent/DK0689836T3/da active
- 1995-06-22 DE DE69522511T patent/DE69522511T2/de not_active Expired - Lifetime
- 1995-06-22 CA CA002152420A patent/CA2152420A1/en not_active Abandoned
- 1995-06-22 AT AT95304449T patent/ATE205085T1/de not_active IP Right Cessation
- 1995-06-22 EP EP95304449A patent/EP0689836B1/de not_active Expired - Lifetime
- 1995-06-22 ES ES95304449T patent/ES2163474T3/es not_active Expired - Lifetime
- 1995-06-26 NO NO952561A patent/NO309454B1/no unknown
- 1995-06-27 ZA ZA955317A patent/ZA955317B/xx unknown
2002
- 2002-07-31 CY CY0200048A patent/CY2290B1/xx unknown

Also Published As

Publication number	Publication date
TW401298B (en)	2000-08-11
JP2852608B2 (ja)	1999-02-03
IL114256A0 (en)	1995-10-31
IL114256A (en)	1999-05-09
US5580880A (en)	1996-12-03
AU707236B2 (en)	1999-07-08
AU2324595A (en)	1996-01-11
ES2163474T3 (es)	2002-02-01
CA2152420A1 (en)	1995-12-28
EP0689836B1 (de)	2001-09-05
NO952561D0 (no)	1995-06-26
EP0689836A1 (de)	1996-01-03
KR960000222A (ko)	1996-01-25
DK0689836T3 (da)	2002-05-06
KR100322042B1 (ko)	2002-11-04
NO309454B1 (no)	2001-02-05
DE69522511D1 (de)	2001-10-11
CY2290B1 (en)	2003-07-04
ZA955317B (en)	1996-02-02
JPH0812575A (ja)	1996-01-16
DE69522511T2 (de)	2002-05-16
NO952561L (no)	1995-12-28

Legal Events

Date	Code	Title
2002-02-15	UEP	Publication of translation of european patent specification
2002-11-15	EEIH	Change in the person of patent owner
2009-03-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69522511D1 (de)	2001-10-11	Spirooxathiolan-quinuclidin-Derivat zur Behandlung von Xerostomie
FR2692264B1 (fr)	1994-08-05	Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
ATE73331T1 (de)	1992-03-15	Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
EE05530B1 (et)	2012-04-16	Gamma-aminov?ihappe derivaate sisaldavad tahked kompositsioonid ja nende saamise meetod
ATE121939T1 (de)	1995-05-15	Ascorbinsäure-tocopheryl-phosphatdiester zur hemmung der maillard-reaktion.
ATE45731T1 (de)	1989-09-15	3-substituierte 2-oxindole-1-carboxamide, als analgetische und antiinflammatorische mittel verwendet.
FI932390A0 (fi)	1993-05-26	Nya hydroxiaminsyra- och N-hydroxiureaderivat samt deras anvaendning
DE60140491D1 (de)	2009-12-24	Verwendung einer pharmazeutischen Zusammensetzung mit einem Para-Aminophenylessigsäurederivat für die Behandlung von entzündlichen Erkrankungen des Magen-Darmtrakts
DE69615984D1 (de)	2001-11-22	Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
DE3586935D1 (de)	1993-02-11	Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen.
ATE184483T1 (de)	1999-10-15	Spirooxathiolan-quinuclidin-derivat zur behandlung des sjögren-syndroms
ATE38991T1 (de)	1988-12-15	In 2-stellung substituierte 1,3propyledendephosphonat-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
ATE79257T1 (de)	1992-08-15	Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
FI933681A0 (fi)	1993-08-20	Antimikrobiellt medel
ATE311191T1 (de)	2005-12-15	Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
DE69209128D1 (de)	1996-04-25	Verwendung von Indazol-Methoxyalkansäure zur Herstellung eines Arzneimittels zur Behandlung von Autoimmunkrankheiten
NO173137C (no)	1993-11-03	Analogifremgangsmaate for fremstilling av terapeutisk aktive forbindelser
ATE34662T1 (de)	1988-06-15	Derivate der benzoesaeure, herstellungsverfahren und anwendung in desinfizierenden und konservierenden arzneimitteln.
ATE66477T1 (de)	1991-09-15	2-guanidino-4-aryl-thiazole fuer die behandlung von peptischen geschwueren.
DE69030502D1 (de)	1997-05-22	Cephalosporinverbindungen und deren herstellung
KR900701278A (ko)	1990-12-01	바이러스 감염 치료용 담즙산
ATE40521T1 (de)	1989-02-15	Verwendung eines substanzgemisches fuer die herstellung eines mittels gegen buergers krankheit.
ATE24834T1 (de)	1987-01-15	Verwendung von beta-(1-adamantyl)-alpha, alphadimethylethylamin zur herstellung eines arzneimittels zur behandlung von otitis externa bei hunden.
ATE167869T1 (de)	1998-07-15	Thiolderivate von gallensäure
DE69819002D1 (de)	2003-11-20	Polyhydroxyalkylpyrazine derivate,deren herstellung und diese enthaltende arzneimitteln